疫苗时代新型冠状病毒肺炎疫情防控策略  

Prevention and control strategy of COVID-19 in the vaccine era

作　　者：陈恩富[1] CHEN Enfu(Department of Communicable Disease Control and Prevention,Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou,Zhejiang 310051,China)

机构地区：[1]浙江省疾病预防控制中心传染病预防控制所,浙江杭州310051

出　　处：《预防医学》2021年第3期221-225,共5页CHINA PREVENTIVE MEDICINE JOURNAL

基　　金：浙江省软科学研究计划“新冠肺炎疫苗应急与常规免疫策略”专项(2021C25018)。

摘　　要：新型冠状病毒肺炎(新冠肺炎)疫情暴发初期,全球主要采取保持社交距离,戴口罩等非药物干预措施。随着新冠疫苗研发的成功以及部分国家的紧急使用,全球新冠肺炎疫情防控开始进入预防接种和非药物干预措施并举的阶段。由于初期疫苗供应短缺,不同国家的接种策略存在差异。为了控制新冠肺炎疫情,全球新冠疫苗接种率需为47%~85%,应增加疫苗产量,制订科学的免疫策略,推进群体免疫进程,提高接种意愿,增加疫苗分配的公平性;加强病毒变异、疫苗有效性和安全性监测,继续开展疫苗研发以应对病毒变异对疫苗有效性的影响。Globally,non-pharmacological interventions,such as keeping social distance and wearing masks,are the primary prevention and control strategy in the early stage of the coronavirus disease 2019(COVID-19)pandemic.The successful development and the urgency use of the COVID-19 vaccines in some countries brings a new stage of combining immunization with non-pharmacological interventions in the fight with COVID-19.For the shortage of vaccines,the immunization strategies vary in countries.To end the pandemic,47%-85%of the population should be immunized with effective COVID-19 vaccines,thus we should boost the yield of vaccines,formulate scientific immunization strategies,promote the mass immunization,improve the willingness of vaccination,and increase the equity of vaccine allocation;meanwhile,we should strengthen the surveillance of virus variation,vaccine effectiveness and safety,and keep on the vaccine research to copy with the potential threat of the virus variation.

关 键 词：新型冠状病毒肺炎 疫苗 非药物干预 免疫策略 

分 类 号：R186[医药卫生—流行病学]